[1] Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez - Chiriboga AS, Lennon VA, Gadoth A, Smith CY, Bryant SC, Klein CJ, Aksamit AJ, Toledano M, Boeve BF, Tillema JM, Flanagan EP. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis[J]. Ann Neurol, 2018, 83: 166-177.
[2] Chen XJ, Li HF, Qiu W, Xu Y, Chen S. Neuroimmune diseases and responsible antibodies[J]. Zhongguo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi, 2021, 28: 283-287. 陈向军, 李海峰, 邱伟, 徐雁, 陈晟. 神经免疫疾病与责任抗体[J]. 中国神经免疫学和神经病学杂志, 2021, 28: 283-287.
[3] Vogrig A, Muñiz-Castrillo S, Desestret V, Joubert B, Honnorat J. Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors[J]. Ther Adv Neurol Disord, 2020, 13: 1756286420932797.
[4] Wollmuth LP, Chan K, Groc L. The diverse and complex modes of action of anti - NMDA receptor autoantibodies[J]. Neuropharmacology, 2021, 194: 108624.
[5] Ding Y, Zhou Z, Chen J, Peng Y, Wang H, Qiu W, Xie W, Zhang J, Wang H. Anti-NMDAR encephalitis induced in mice by active immunization with a peptide from the amino-terminal domain of the GluN1 subunit[J]. J Neuroinflammation, 2021, 18: 53.
[6] Zekeridou A, Pittock SJ. Synaptic autoimmunity: new insights into LGI1 antibody - mediated neuronal dysfunction[J]. Brain, 2020, 143: 1622-1625.
[7] Gardoni F, Stanic J, Scheggia D, Benussi A, Borroni B, Di Luca M. NMDA and AMPA receptor autoantibodies in brain disorders: from molecular mechanisms to clinical features[J]. Cells, 2021, 10: 77.
[8] Brändle SM, Cerina M, Weber S, Held K, Menke AF, Alcalá C, Gebert D, Herrmann AM, Pellkofer H, Gerdes LA, Bittner S, Leypoldt F, Teegen B, Komorowski L, Kümpfel T, Hohlfeld R, Meuth SG, Casanova B, Melzer N, Beltrán E, Dornmair K. Cross - reactivity of a pathogenic autoantibody to a tumor antigen in GABAA receptor encephalitis[J]. Proc Natl Acad Sci USA, 2021, 118: e1916337118.
[9] Nibber A, Mann EO, Pettingill P, Waters P, Irani SR, Kullmann DM, Vincent A, Lang B. Pathogenic potential of antibodies to the GABAB receptor[J]. Epilepsia Open, 2017, 2: 355-359.
[10] Kreye J, Wright SK, van Casteren A, Stöffler L, Machule ML, Reincke SM, Nikolaus M, van Hoof S, Sanchez - Sendin E, Homeyer MA, Cordero Gómez C, Kornau HC, Schmitz D, Kaindl AM, Boehm-Sturm P, Mueller S, Wilson MA, Upadhya MA, Dhangar DR, Greenhill S, Woodhall G, Turko P, Vida I, Garner CC, Wickel J, Geis C, Fukata Y, Fukata M, Prüss H. Encephalitis patient - derived monoclonal GABAA receptor antibodies cause epileptic seizures[J]. J Exp Med, 2021, 218: e20210012.
[11] Jain A, Lancaster E, Dalmau J, Balice - Gordon RJ. Autoantibodies in the CSF of anti - GABAB receptor encephalitis patients block activation of GABAB receptors in vitro [J]. Ann Neurol, 2015, 78: S77.
[12] Mikasova L, De Rossi P, Bouchet D, Georges F, Rogemond V, Didelot A, Meissirel C, Honnorat J, Groc L. Disrupted surface cross - talk between NMDA and Ephrin - B2 receptors in anti - NMDA encephalitis [J]. Brain, 2012, 135(Pt 5): 1606-1621.
[13] Carceles - Cordon M, Mannara F, Aguilar E, Castellanos A, Planagumà J, Dalmau J. NMDAR antibodies alter dopamine receptors and cause psychotic behavior in mice[J]. Ann Neurol, 2020, 88: 603-613.
[14] Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, Geis C, Lancaster E, Titulaer MJ, Rosenfeld MR, Graus F. An update on anti - NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models[J]. Lancet Neurol, 2019, 18: 1045-1057.
[15] Shan W, Yang H, Wang Q. Neuronal surface antibody - medicated autoimmune encephalitis (limbic encephalitis) in China: a multiple - center, retrospective study [J]. Front Immunol, 2021, 12: 621599.
[16] O'Connor K, Waters P, Komorowski L, Zekeridou A, Guo CY, Mgbachi VC, Probst C, Mindorf S, Teegen B, Gelfand JM, Geschwind MD, Lennon V, Pittock SJ, McKeon A. GABAA receptor autoimmunity: a multicenter experience[J]. Neurol Neuroimmunol Neuroinflamm, 2019, 6: e552.
[17] Gresa - Arribas N, Planagumà J, Petit - Pedrol M, Kawachi I, Katada S, Glaser CA, Simabukuro MM, Armangué T, Martínez-Hernández E, Graus F, Dalmau J. Human neurexin - 3α antibodies associate with encephalitis and alter synapse development [J]. Neurology, 2016, 86: 2235-2242.
[18] Spatola M, Sabater L, Planagumà J, Martínez - Hernandez E, Armangué T, Prüss H, Iizuka T, Caparó Oblitas RL, Antoine JC, Li R, Heaney N, Tubridy N, Munteis Olivas E, Rosenfeld MR, Graus F, Dalmau J. Encephalitis with mGluR5 antibodies: symptoms and antibody effects[J]. Neurology, 2018, 90: e1964-1972.
[19] Dale RC, Merheb V, Pillai S, Wang D, Cantrill L, Murphy TK, Ben-Pazi H, Varadkar S, Aumann TD, Horne MK, Church AJ, Fath T, Brilot F. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders[J]. Brain, 2012, 135(Pt 11): 3453-3468.
[20] Zhang TY, Cai MT, Zheng Y, Lai QL, Shen CH, Qiao S, Zhang YX. Anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor encephalitis: a review[J]. Front Immunol, 2021, 12: 652820.
[21] Ghimire P, Khanal UP, Gajurel BP, Karn R, Rajbhandari R, Paudel S, Gautam N, Ojha R. Anti - LGI1, anti - GABABR, and anti - CASPR2 encephalitides in Asia: a systematic review[J]. Brain Behav, 2020, 10: e01793.
[22] Qin X, Yang H, Zhu F, Wang Q, Shan W. Clinical character of CASPR2 autoimmune encephalitis: a multiple center retrospective study[J]. Front Immunol, 2021, 12: 652864.
[23] Alexopoulos H, Akrivou S, Mastroyanni S, Antonopoulou M, Dinopoulos A, Giorgi M, Konstantinou K, Kouremenos E, Lariou M, Naoumis D, Pavlidou E, Pavlou E, Voudris K, Vlachoyiannopoulos P, Dalakas MC. Postherpes simplex encephalitis: a case series of viral - triggered autoimmunity, synaptic autoantibodies and response to therapy[J]. Ther Adv Neurol Disord, 2018, 11: 1756286418768778.
[24] Joubert B, Dalmau J. The role of infections in autoimmune encephalitides [J]. Rev Neurol (Paris), 2019, 175: 420-426.
[25] Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E, Llufriu S, Muchart J, Erro ME, Abraira L, Moris G, Monros-Giménez L, Corral-Corral Í, Montejo C, Toledo M, Bataller L, Secondi G, Ariño H, Martínez-Hernández E, Juan M, Marcos MA, Alsina L, Saiz A, Rosenfeld MR, Graus F, Dalmau J; Spanish Herpes Simplex Encephalitis Study Group. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis [J]. Lancet Neurol, 2018, 17: 760-772.
[26] Bradshaw MJ, Pawate S, Lennon VA, Bloch KC, Brown KM. Herpes simplex virus 1 encephalitis associated with voltage - gated calcium channel autoimmunity[J]. Neurology, 2015, 85: 2176-2177.
[27] Moloney PB, Hutchinson S, Heskin J, Mulcahy F, Langan Y, Conlon NP, Linas BP, Takahashi C, Cervantes - Arslanian AM. Possible N - methyl - D - aspartate receptor antibody - mediated encephalitis in the setting of HIV cerebrospinal fluid escape [J]. J Neurol, 2020, 267: 1348-1352.
[28] Platt MP, Bolding KA, Wayne CR, Chaudhry S, Cutforth T, Franks KM, Agalliu D. Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of postinfectious autoimmune encephalitis[J]. Proc Natl Acad Sci USA, 2020, 117: 6708-6716.
[29] Dalmau J, Graus F. Antibody - mediated encephalitis[J]. N Engl J Med, 2018, 378: 840-851.
[30] Piquet AL, Clardy SL. Infection, immunodeficiency, and inflammatory diseases in autoimmune neurology[J]. Semin Neurol, 2018, 38: 379-391.
[31] Prüss H. Autoantibodies in neurological disease[J]. Nat Rev Immunol, 2021, 21: 798-813.
[32] Makuch M, Wilson R, Al - Diwani A, Varley J, Kienzler AK, Taylor J, Berretta A, Fowler D, Lennox B, Leite MI, Waters P, Irani SR. N - methyl - D - aspartate receptor antibody production from germinal center reactions: therapeutic implications[J]. Ann Neurol, 2018, 83: 553-561.
[33] Jiang XY, Lei S, Zhang L, Liu X, Lin MT, Blumcke I, Piao YS, Zhou D, Li JM. Co-expression of NMDA-receptor subunits NR1, NR2A, and NR2B in dysplastic neurons of teratomas in patients with paraneoplastic NMDA - receptor - encephalitis: a retrospective clinico - pathology study of 159 patients[J]. Acta Neuropathol Commun, 2020, 8: 130.
[34] Chefdeville A, Treilleux I, Mayeur ME, Couillault C, Picard G, Bost C, Mokhtari K, Vasiljevic A, Meyronet D, Rogemond V, Psimaras D, Dubois B, Honnorat J, Desestret V. Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis [J]. Acta Neuropathol Commun, 2019, 7: 38.
[35] van Coevorden - Hameete MH, de Bruijn MAAM, de Graaff E, Bastiaansen DAEM, Schreurs MWJ, Demmers JAA, Ramberger M, Hulsenboom ESP, Nagtzaam MMP, Boukhrissi S, Veldink JH, Verschuuren JJGM, Hoogenraad CC, Sillevis Smitt PAE, Titulaer MJ. The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies[J]. Brain, 2019, 142: 1631-1643.
[36] Gozzard P, Woodhall M, Chapman C, Nibber A, Waters P, Vincent A, Lang B, Maddison P. Paraneoplastic neurologic disorders in small cell lung carcinoma: a prospective study[J]. Neurology, 2015, 85: 235-239.
[37] Guasp M, Landa J, Martinez-Hernandez E, Sabater L, Iizuka T, Simabukuro M, Nakamura M, Kinoshita M, Kurihara M, Kaida K, Bruna J, Kapetanovic S, Sánchez P, Ruiz-García R, Naranjo L, Planagumà J, Muñoz-Lopetegi A, Bataller L, Saiz A, Dalmau J, Graus F. Thymoma and autoimmune encephalitis: clinical manifestations and antibodies [J]. Neurol Neuroimmunol Neuroinflamm, 2021, 8: e1053.
[38] Spatola M, Petit Pedrol M, Maudes E, Simabukuro M, Muñiz - Castrillo S, Pinto AL, Wandinger KP, Spiegler J, Schramm P, Dutra LA, Iorio R, Kornblum C, Bien CG, Höftberger R, Leypoldt F, Titulaer MJ, Sillevis Smitt P, Honnorat J, Rosenfeld MR, Graus F, Dalmau J. Clinical features, prognostic factors, and antibody effects in anti - mGluR1 encephalitis [J]. Neurology, 2020, 95: e3012-3025.
[39] Kapadia RK, Ney DE, Hannan M, Farley M, Pastula DM, Piquet AL. Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab[J]. J Neuroimmunol, 2020, 344: 577259.
[40] Segal Y, Bukstein F, Raz M, Aizenstein O, Alcalay Y, Gadoth A. PD-1-inhibitor-induced PCA-2 (MAP1B) autoimmunity in a patient with renal cell carcinoma[J]. Cerebellum, 2021. [Epub ahead of print]
[41] SChevalier K, Noel N, Benoudiba F, Chrétien P, Hacein - Bey - Abina S, Lambotte O. Anti - Ma2 antibody encephalitis associated with Sjogren's syndrome[J]. Rev Med Interne, 2021, 42: 575-578.
[42] Piepgras J, Müller A, Steffen F, Lotz J, Loquai C, Zipp F, Dresel C, Bittner S. Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibody - positive autoimmune encephalitis under immune checkpoint inhibitor therapy[J]. Eur J Neurol, 2021, 28: 1086-1089.
[43] Vogrig A, Muñiz - Castrillo S, Joubert B, Picard G, Rogemond V, Marchal C, Chiappa AM, Chanson E, Skowron F, Leblanc A, Ducray F, Honnorat J. Central nervous system complications associated with immune checkpoint inhibitors[J]. J Neurol Neurosurg Psychiatry, 2020, 91: 772-778.
[44] Chang H, Shin YW, Keam B, Kim M, Im SA, Lee ST. HLA - B27 association of autoimmune encephalitis induced by PD-L1 inhibitor [J]. Ann Clin Transl Neurol, 2020, 7: 2243-2250.
[45] Nersesjan V, McWilliam O, Krarup LH, Kondziella D. Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: a systematic review [J]. Neurology, 2021, 97: e191-202.
[46] Velasco R, Villagrán M, Jové M, Simó M, Vilariño N, Alemany M, Palmero R, Martínez - Villacampa MM, Nadal E, Bruna J. Encephalitis induced by immune checkpoint inhibitors: a systematic review[J]. JAMA Neurol, 2021, 78: 864-873.
[47] Shen CH, Fang GL, Yang F, Cai MT, Zheng Y, Fang W, Guo Y, Zhang YX, Ding MP. Seizures and risk of epilepsy in anti- NMDAR, anti - LGI1, and anti - GABABR encephalitis[J]. Ann Clin Transl Neurol, 2020, 7: 1392-1399.
[48] Suga H, Yanagida A, Kanazawa N, Ohara H, Kitagawa T, Hayashi M, Onozawa Y, Nagata N, Kaneko J, Kitamura E, Nishiyama K, Iizuka T. Status epilepticus suspected autoimmune: neuronal surface antibodies and main clinical features [J]. Epilepsia, 2021, 62: 2719-2731.
[49] Bozzetti S, Rossini F, Ferrari S, Delogu R, Cantalupo G, Marchioretto F, Zanette G, Zanoni T, Turatti M, Vitale G, Cadaldini M, Rossi F, Di Tizio L, Zuco C, Maniscalco GT, Soldani F, Monaco S, Trinka E, Hoeftberger R, Mariotto S. Epileptic seizures of suspected autoimmune origin: a multicentre retrospective study [J]. J Neurol Neurosurg Psychiatry, 2020, 91: 1145-1153.
[50] Yeshokumar AK, Coughlin A, Fastman J, Psaila K, Harmon M, Randell T, Schorr EM, Han H, Hoang H, Soudant C, Jette N. Seizures in autoimmune encephalitis: a systematic review and quantitative synthesis[J]. Epilepsia, 2021, 62: 397-407.
[51] Stanciu GD, Bild V, Ababei DC, Rusu RN, Beschea Chiriac SI, Rezuş E, Luca A. Relevance of surface neuronal protein autoantibodies as biomarkers in seizure - associated disorders [J]. Int J Mol Sci, 2019, 20: 4529.
[52] Geis C, Planagumà J, Carreño M, Graus F, Dalmau J. Autoimmune seizures and epilepsy[J]. J Clin Invest, 2019, 129: 926-940.
[53] Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, Schott JM, Armstrong RJ, S Zagami A, Bleasel A, Somerville ER, Smith SM, Vincent A. Faciobrachial dystonic seizures precede LGI1 antibody limbic encephalitis[J]. Ann Neurol, 2011, 69: 892-900.
[54] Spatola M, Petit-Pedrol M, Simabukuro MM, Armangue T, Castro FJ, Barcelo Artigues MI, Julià Benique MR, Benson L, Gorman M, Felipe A, Caparó Oblitas RL, Rosenfeld MR, Graus F, Dalmau J. Investigations in GABAA receptor antibody - associated encephalitis [J]. Neurology, 2017, 88: 1012-1020.
[55] Nissen MS, Ørvik MS, Nilsson AC, Ryding M, Lydolph M, Blaabjerg M. NMDA - receptor encephalitis in Denmark from 2009 to 2019: a national cohort study[J]. J Neurol, 2021. [Epub ahead of print]
[56] Banks SA, Sechi E, Flanagan EP. Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression[J]. Ther Adv Neurol Disord, 2021, 14: 1756286421998906.
[57] Zeng W, Cao L, Zheng J, Yu L. Clinical characteristics and long - term prognosis of relapsing anti - N - methyl - D - aspartate receptor encephalitis: a retrospective, multicenter, self - controlled study[J]. Neurol Sci, 2021, 42: 199-207.
[58] Hansen N, Malchow B, Zerr I, Stöcker W, Wiltfang J, Timäus C. Neural cell - surface and intracellular autoantibodies in patients with cognitive impairment from a memory clinic cohort [J]. J Neural Transm (Vienna), 2021, 128: 357-369.
[59] Brunetti V, Della Marca G, Spagni G, Iorio R. Immunotherapy improves sleep and cognitive impairment in anti - IgLON5 encephalopathy [J]. Neurol Neuroimmunol Neuroinflamm, 2019, 6: e577.
[60] Doss S, Wandinger KP, Hyman BT, Panzer JA, Synofzik M, Dickerson B, Mollenhauer B, Scherzer CR, Ivinson AJ, Finke C, Schöls L, Müller Vom Hagen J, Trenkwalder C, Jahn H, Höltje M, Biswal BB, Harms L, Ruprecht K, Buchert R, Höglinger GU, Oertel WH, Unger MM, Körtvélyessy P, Bittner D, Priller J, Spruth EJ, Paul F, Meisel A, Lynch DR, Dirnagl U, Endres M, Teegen B, Probst C, Komorowski L, Stöcker W, Dalmau J, Prüss H. High prevalence of NMDA receptor IgA/ IgM antibodies in different dementia types[J]. Ann Clin Transl Neurol, 2014, 1: 822-832.
[61] Gibson LL, McKeever A, Cullen AE, Nicholson TR, Aarsland D, Zandi MS, Pollak TA. Neuronal surface autoantibodies in dementia: a systematic review and meta-analysis[J]. J Neurol, 2021, 268: 2769-2779.
[62] Kruse JL, Lapid MI, Lennon VA, Klein CJ, Toole OO, Pittock SJ, Strand EA, Frye MA, McKeon A. Psychiatric autoimmunity: N - methyl - D - aspartate receptor IgG and beyond [J]. Psychosomatics, 2015, 56: 227-241.
[63] Soto-Rincón CA, Castillo-Torres SA, Cantú-García DA, Estrada-Bellmann I, Chávez - Luévanos B, Marfil A. The poor insane Ophelia: reconsidering Ophelia syndrome [J]. Arq Neuropsiquiatr, 2019, 77: 828-831.
[64] Muñoz - Lopetegi A, Graus F, Dalmau J, Santamaria J. Sleep disorders in autoimmune encephalitis[J]. Lancet Neurol, 2020, 19: 1010-1022.
[65] Ariño H, Muñoz-Lopetegi A, Martinez-Hernandez E, Armangue T, Rosa-Justicia M, Escudero D, Matos N, Graus F, Sugranyes G, Castro - Fornieles J, Compte A, Dalmau J, Santamaria J. Sleep disorders in anti - NMDAR encephalitis[J]. Neurology, 2020, 95: e671-684.
[66] Devine MF, Feemster JC, Lieske EA, McCarter SJ, Sandness DJ, Steele T, Timm PC, Mandrekar J, Boeve BF, Silber MH, Dubey D, McKeon A, St Louis EK. Objective sleep profile in LGI1/CASPR2 autoimmunity[J]. Sleep, 2021. [Epub ahead of print]
[67] Gaig C, Iranzo A, Cajochen C, Vilaseca I, Embid C, Dalmau J, Graus F, Santamaria J. Characterization of the sleep disorder of anti-IgLON5 disease [J]. Sleep, 2019, 42: zsz133.
[68] Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, Appendino JP, Lucchinetti CF, Matsumoto JY, Pittock SJ, Sandroni P, Tippmann - Peikert M, Wirrell EC, McKeon A. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients[J]. Neurology, 2014, 83: 1797-1803.
[69] Al - Diwani A, Handel A, Townsend L, Pollak T, Leite MI, Harrison PJ, Lennox BR, Okai D, Manohar SG, Irani SR. The psychopathology of NMDAR - antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data [J]. Lancet Psychiatry, 2019, 6: 235-246.
[70] Lin N, Hao H, Guan H, Sun H, Liu Q, Lu Q, Jin L, Ren H, Huang Y. Sleep disorders in leucine - rich glioma - inactivated protein 1 and contactin protein - like 2 antibody - associated diseases [J]. Front Neurol, 2020, 11: 696.
[71] Pruetarat N, Netbaramee W, Pattharathitikul S, Veeravigrom M. Clinical manifestations, treatment outcomes, and prognostic factors of pediatric anti - NMDAR encephalitis in tertiary care hospitals: a multicenter retrospective/prospective cohort study [J]. Brain Dev, 2019, 41: 436-442.
[72] Giri YR, Parrill A, Damodar S, Fogel J, Ayed N, Syed M, Korie I, Ayyanar S, Typhair C, Hashmi S. Anti - N - methyl - D - aspartate receptor (NMDAR) encephalitis in children and adolescents: a systematic review and quantitative analysis of reported cases[J]. J Can Acad Child Adolesc Psychiatry, 2021, 30: 236-248.
[73] Baizabal - Carvallo JF, Stocco A, Muscal E, Jankovic J. The spectrum of movement disorders in children with anti - NMDA receptor encephalitis[J]. Mov Disord, 2013, 28: 543-547.
[74] van Sonderen A, Petit - Pedrol M, Dalmau J, Titulaer MJ. The value of LGI1, Caspr2 and voltage - gated potassium channel antibodies in encephalitis[J]. Nat Rev Neurol, 2017, 13: 290-301.
[75] Gadoth A, Pittock SJ, Dubey D, McKeon A, Britton JW, Schmeling JE, Smith A, Kotsenas AL, Watson RE, Lachance DH, Flanagan EP, Lennon VA, Klein CJ. Expanded phenotypes and outcomes among 256 LGI1/CASPR2 - IgG - positive patients [J]. Ann Neurol, 2017, 82: 79-92.
[76] Balint B, Jarius S, Nagel S, Haberkorn U, Probst C, Blöcker IM, Bahtz R, Komorowski L, Stöcker W, Kastrup A, Kuthe M, Meinck HM. Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies[J]. Neurology, 2014, 82: 1521-1528.
[77] Carvajal - González A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, Lang B, Pettingill P, Carr A, Sheerin UM, Press R, Press R, Lunn MP, Lim M, Maddison P, Meinck HM, Vandenberghe W, Vincent A. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes [J]. Brain, 2014, 137(Pt 8): 2178-2192.
[78] Graus F, Saiz A, Dalmau J. GAD antibodies in neurological disorders: insights and challenges[J]. Nat Rev Neurol, 2020, 16: 353-365.
[79] Mizutani Y, Adachi S, Nakano S, Hayashi K, Higashi A, Kikuchi K, Maeda T, Murate K, Shima S, Iizuka T, Ueda A, Ito M, Watanabe H. Severe dysautonomia in glycine receptor antibody - positive progressive encephalomyelitis with rigidity and myoclonus (PERM): a case report[J]. Auton Neurosci, 2022, 237: 102910.
[80] Martinez-Hernandez E, Ariño H, Mckeon A, Iizuka T, Titulaer MJ, Simabukuro MM, Lancaster E, Petit-Pedrol M, Planagumà J, Blanco Y, Harvey RJ, Saiz A, Graus F, Dalmau J. Clinical and immunologic investigations in patients with stiff - person spectrum disorder [J]. JAMA Neurol, 2016, 73: 714-720.
[81] Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M, Roberts K, Martinez - Hernandez E, Rosenfeld MR, Balice - Gordon R, Graus F, Rudy B, Dalmau J. Encephalitis and antibodies to dipeptidyl - peptidase - like protein - 6, a subunit of Kv4.2 potassium channels [J]. Ann Neurol, 2013, 73: 120-128.
[82] Shojima Y, Nishioka K, Watanabe M, Jo T, Tanaka K, Takashima H, Noda K, Okuma Y, Urabe T, Yokoyama K, Hattori N. Clinical characterization of definite autoimmune limbic encephalitis: a 30-case series[J]. Intern Med, 2019, 58: 3369-3378.
[83] Baumgartner A, Rauer S, Mader I, Meyer PT. Cerebral FDG - PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types[J]. J Neurol, 2013, 260: 2744-2753.
[84] Liu X, Yu T, Zhao X, Li G, Lv R, Ai L, Wang Q. 18F - fluorodeoxy - glucose positron emission tomography pattern and prognostic predictors in patients with anti - GABAB receptor encephalitis[J]. CNS Neurosci Ther, 2021. [Epub ahead of print]
[85] Laurido - Soto O, Brier MR, Simon LE, McCullough A, Bucelli RC, Day GS. Patient characteristics and outcome associations in AMPA receptor encephalitis[J]. J Neurol, 2019, 266: 450-460.
[86] Masangkay N, Basu S, Moghbel M, Kwee T, Alavi A. Brain 18F- FDG - PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings [J]. Nucl Med Commun, 2014, 35: 1038-1046.
[87] Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system[J]. Physiol Rev, 2017, 97: 839-887.
[88] Probasco JC, Solnes L, Nalluri A, Cohen J, Jones KM, Zan E, Javadi MS, Venkatesan A. Decreased occipital lobe metabolism by FDG - PET/CT: an anti - NMDA receptor encephalitis biomarker[J]. Neurol Neuroimmunol Neuroinflamm, 2017, 5: e413.
[89] Wei YC, Tseng JR, Wu CL, Su FC, Weng WC, Hsu CC, Chang KH, Wu CF, Hsiao IT, Lin CP. Different FDG - PET metabolic patterns of anti - AMPAR and anti - NMDAR encephalitis: case report and literature review[J]. Brain Behav, 2020, 10: e01540.
[90] Ge J, Deng B, Guan Y, Bao W, Wu P, Chen X, Zuo C. Distinct cerebral 18F - FDG PET metabolic patterns in anti - N - methyl-D-aspartate receptor encephalitis patients with different trigger factors [J]. Ther Adv Neurol Disord, 2021, 14: 1756286421995635.
[91] Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres - Vega E, Contreras A, Giometto B, Compta Y, Embid C, Vilaseca I, Iranzo A, Santamaría J, Dalmau J, Graus F. A novel non - rapid - eye movement and rapid - eye - movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post - mortem study[J]. Lancet Neurol, 2014, 13: 575-586.
[92] Giannini G, Calandra - Buonaura G, Mastrolilli F, Righini M, Bacchi-Reggiani ML, Cecere A, Barletta G, Guaraldi P, Provini F, Cortelli P. Early stridor onset and stridor treatment predict survival in 136 patients with MSA[J]. Neurology, 2016, 87: 1375-1383.
[93] Patterson KR, Dalmau J, Lancaster E. Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia[J]. Ann Neurol, 2018, 83: 40-51.
[94] Koneczny I, Yilmaz V, Lazaridis K, Tzartos J, Lenz TL, Tzartos S, Tüzün E, Leypoldt F. Common denominators in the immunobiology of IgG4 autoimmune diseases: what do glomerulonephritis, pemphigus vulgaris, myasthenia gravis, thrombotic thrombocytopenic purpura and autoimmune encephalitis have in common[J]? Front Immunol, 2021, 11: 605214.
[95] van Coevorden - Hameete MH, de Graaff E, Titulaer MJ, Hoogenraad CC, Sillevis Smitt PA. Molecular and cellular mechanisms underlying anti - neuronal antibody mediated disorders of the central nervous system[J]. Autoimmun Rev, 2014, 13: 299-312.
[96] Gadoth A, Zekeridou A, Klein CJ, Thoreson CJ, Majed M, Dubey D, Flanagan EP, McKeon A, Jenkins SM, Lennon VA, Pittock SJ. Elevated LGI1 - IgG CSF index predicts worse neurological outcome[J]. Ann Clin Transl Neurol, 2018, 5: 646-650.
[97] Li TR, Zhang YD, Wang Q, Shao XQ, Li ZM, Lv RJ. Intravenous methylprednisolone or immunoglobulin for anti - glutamic acid decarboxylase 65 antibody autoimmune encephalitis: which is better [J]? BMC Neurosci, 2020, 21: 13.
[98] Parwani J, Ortiz JF, Alli A, Lalwani A, Ruxmohan S, Tamton H, Cuenca VD, Gonzalez D, Anwer F, Eissa - Garcés A, Alzamora IM, Paez M. Understanding seizures and prognosis of the extreme delta brush pattern in anti - N - methyl - D - aspartate (NMDA) receptor encephalitis: a systematic review[J]. Cureus, 2021, 13: e18154.
[99] de Montmollin E, Demeret S, Brulé N, Conrad M, Dailler F, Lerolle N, Navellou JC, Schwebel C, Alves M, Cour M, Engrand N, Tonnelier JM, Maury E, Ruckly S, Picard G, Rogemond V, Magalhaes É, Sharshar T, Timsit JF, Honnorat J, Sonneville R; ENCEPHALITICA Study Group. Anti - N - methyl - D - aspartate receptor encephalitis in adult patients requiring intensive care[J]. Am J Respir Crit Care Med, 2017, 195: 491-499.
[100] Zhang Y, Liu G, Jiang M, Chen W, He Y, Su Y. Clinical characteristics and prognosis of severe anti - N - methyl - D - aspartate receptor encephalitis patients[J]. Neurocrit Care, 2018, 29: 264-272.
[101] Mehr SR, Neeley RC, Wiley M, Kumar AB. Profound autonomic instability complicated by multiple episodes of cardiac asystole and refractory bradycardia in a patient with anti - NMDA encephalitis[J]. Case Rep Neurol Med, 2016, 2016: 7967526.
[102] Li TR, Zhang YD, Wang Q, Shao XQ, Lyu DY, Lv RJ. Clinical characteristics and long - term prognosis of anti - LGI1 encephalitis: a single-center cohort study in Beijing, China[J]. Front Neurol, 2021, 12: 674368.
[103] Li Y, Song F, Liu W, Wang Y. Clinical features of nine cases of leucine-rich glioma inactivated 1 protein antibody-associated encephalitis [J]. Acta Neurol Belg, 2021, 121: 889-897.
[104] Society of Neurology, Chinese Medical Association. Consensus of Chinese experts on diagnosis and treatment of autoimmune encephalitis[J]. Zhonghua Shen Jing Ke Za Zhi, 2017, 50: 91-98. 中华医学会神经病学分会. 中国自身免疫性脑炎诊治专家共识[J]. 中华神经科杂志, 2017, 50: 91-98. |